The first twice-daily injectable HIV prevention drug based on lenacapavir has received CHMP recommendation for authorization, promising an effective and affordable solution.
Cristina Petrache
Health
Foto pexels.com
Always see our news on Google
Lenacapavir is the first twice-daily injectable drug for the prevention of HIV infection, with 99.9% efficacy in clinical trials. Recommended by the CHMP, this treatment simplifies prevention by eliminating the need for daily tablets. In Romania, where the cost of HIV treatment is high, the new PrEP could reduce costs and improve access for vulnerable people. Approved at European level, this drug represents a significant opportunity to transform HIV prevention into public health policy.
Sources
Europa se apropie de aprobarea primului tratament PrEP injectabil cu administrare la 6 luni - o şansă uriaşă pentru prevenţia HIV în România
Europa se apropie de aprobarea primului tratament PrEP injectabil cu administrare la 6 luni - o șansă uriașă pentru prevenția HIV în România
Omenirea, mai aproape ca niciodată de a opri virusul HIV. Europa a autorizat tratamentul revoluționar
E.U. regulator approves injectable HIV drug that experts say could help stop transmission
EU regulator approves injectable HIV drug that experts say could help stop transmission
Latest News
22:41
Armed attack with multiple victims in Prospect Hill, North Carolina
22:20
An explosive drone was found on the runway of the airport in Leipzig / The German police deployed a bomb disposal robot
21:47
Iran and Oman have agreed on a shipping route through the Strait of Hormuz
21:38
919 primaries have not yet registered on Ghiseul.ro / Oana Gheorghiu: The deadline is August 25
21:20
The authorities of the Republic of Moldova and Ukraine are preparing anti-crisis measures following the decrease in the level of the Dniester River.
See more news
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
.webp)
